| abstract |
Novel methods of treating generalized myasthenia gravis in a subject are provided. These methods generally include administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments, the FcRn antagonist binds FcRn with increased affinity and decreased pH dependence relative to the native Fc region. |